glimepiride has been researched along with dinoprost in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukatsu, A; Hayashi, T; Iguchi, A; Kano, H; Matsui-Hirai, H; Miyazaki, A; Nomura, N; Suzuki, Y; Tsunekawa, T | 1 |
| Hur, KY; Jin, SM; Kim, G; Kim, JH; Lee, MK; Oh, S | 1 |
2 trial(s) available for glimepiride and dinoprost
| Article | Year |
|---|---|
Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects.
Topics: Adiponectin; Aged; Diabetes Mellitus, Type 2; Dinoprost; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Osmolar Concentration; Plasminogen Activator Inhibitor 1; Proteins; Sulfonylurea Compounds; Tumor Necrosis Factor-alpha | 2003 |
The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dinoprost; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Vildagliptin | 2017 |